For example, among EGFR‐altered NSCLC patients, TP53 alterations reduce responsiveness to EGFR‐TKIs and worsen prognosis,46, 47 KRAS alteration was significantly associated with an absence of response to EGFR‐TKI,48 and PIK3CA alteration was associated with shorter OS in some studies but do not appear to impact response rates and PFS with first‐line or second‐line EGFR‐TKI therapy. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.